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Background:  Left ventricular systolic dysfunction (LVSD) is a major problem with no established therapies that directly enhance cardiac 
function. Neuregulin may enhance recovery of LV function.
methods:  A first in human Phase 1 placebo-controlled dose-escalation double-blind study examining safety and tolerability of a single IV 
infusion of the neuregulin, cimaglermin (GGF2) was done. Subjects had echocardiographic measures of cardiac function obtained at days 
0,8,14, 28, and 90.
results:  40 patients(57.4+/-1.6years(SE)),88%(n=33) male, 60% NYHA class 2/40% NYHA class 3 HF and 73%(n=29) with ischemic 
etiology,were all on optimal medical therapy and given placebo or one of 7 ascending doses of GGF2. Treated groups were consolidated 
into low dose(3 lowest doses: 0.007- 0.063 mg/kg), high dose(4 highest doses: 0.189 - 1.512 mg/kg) and placebo. No demographic 
differences in all groups was noted and GGF2 had no effect on hematologic or the majority of biochemical safety labs. GGF2 did result in 
transitory nausea, headache, fatigue, and diarrhea more commonly than placebo. A dose-limiting toxicity of transient elevated liver tests 
(Hy’s Law) occurred in one patient at the highest dose. The absolute change in mean LVEF in high dose GGF2 group was significantly 
different from placebo and low dose over 90 days (Figure 1).
conclusion:  There appears to be a sustained beneficial effect on cardiac function for up to 90 days of a single dose of GGF2 with 
acceptable safety and tolerability at doses <1.5 mg/kg. 
